Bank of America
ANTX icon

Bank of America’s AN2 Therapeutics ANTX Stock Holding History

Bank of America’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.35M Buy
393,702
+8,390
+2% +$17.3K ﹤0.01% 4349
2025
Q4 		$439K Buy
385,312
+2
+0% +$2 ﹤0.01% 4974
2025
Q3 		$489K Sell
385,310
-201
-0.1% -$230 ﹤0.01% 5801
2025
Q2 		$409K Buy
385,511
+28
+0% +$33 ﹤0.01% 5827
2025
Q1 		$524K Buy
385,483
+8
+0% +$10 ﹤0.01% 5623
2024
Q4 		$532K Buy
385,475
+369,265
+2,278% +$448K ﹤0.01% 5484
2024
Q3 		$17.3K Buy
16,210
+574
+4% +$996 ﹤0.01% 6775
2024
Q2 		$33.6K Buy
15,636
+664
+4% +$1.58K ﹤0.01% 6613
2024
Q1 		$48.7K Sell
14,972
-6,922
-32% -$75.3K ﹤0.01% 6522
2023
Q4 		$449K Buy
21,894
+18,799
+607% +$315K ﹤0.01% 5571
2023
Q3 		$49.8K Sell
3,095
-9,121
-75% -$103K ﹤0.01% 6510
2023
Q2 		$104K Sell
12,216
-13,700
-53% -$98.5K ﹤0.01% 6186
2023
Q1 		$256K Buy
25,916
+1,202
+5% +$13.4K ﹤0.01% 5794
2022
Q4 		$236K Buy
24,714
+11,548
+88% +$155K ﹤0.01% 5825
2022
Q3 		$229K Buy
13,166
+11,527
+703% +$134K ﹤0.01% 5904
2022
Q2 		$13K Buy
+1,639
New +$21.7K ﹤0.01% 7311

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Bank of America's ANTX Position: Q1 2026 in Review

Bank of America increased its AN2 Therapeutics (ANTX) stake by 2.2% in Q1 2026, buying an estimated $17.3K and bringing the position to 393,702 shares worth $1.35M. The position accounts for ﹤0.01% of the portfolio, ranked #4349.

Bank of America first reported a position in ANTX in Q2 2022 and has held it in 16 quarters since. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • Bank of America held 393,702 shares of AN2 Therapeutics worth $1.35M as of Q1 2026.
  • Bank of America bought 8,390 AN2 Therapeutics shares in Q1 2026, an estimated $17.3K.
  • AN2 Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4349 holding.
  • Bank of America first reported a position in AN2 Therapeutics in Q2 2022 and has held it in 16 quarters since.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.